AI Summary
✦ ClarthaValuation Metrics
Trading 23.6% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +1.71). Confidence: 89%.
Live forward EPS implies next-12-month EPS of ₹267.55. Applying the stock's normalized valuation corridor produces a fair range of ₹6,429.23 to ₹7,507.45, with base value near ₹6,744.94 (+13.1% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹267.55
Forward P/E
22.3x
Base Fair Value
₹6,744.94
Fair Range
₹6,429.23 - ₹7,507.45
Upside To Base
+13.1%
Estimate Source
Live forward EPS
Growth Estimate
+45.3%
5Y Average
24.12
Current
31.15
Overvalued
28.06
Undervalued
24.03
5Y Average
5.51
Current
6.91
Overvalued
6.34
Undervalued
4.68
5Y Average
16.35
Current
18.88
Overvalued
18.89
Undervalued
13.87
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.0x Undervalued | -54% vs avg | +43.4% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.8x Undervalued | -29% vs avg | +45.4% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Undervalued | -29% vs avg | -25.8% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Undervalued | -37% vs avg | +31.7% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 37.5x Undervalued | -39% vs avg | +29.9% |
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -49% vs avg | +22.1% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 162.0x Premium | +163% vs avg | -52.7% |
ASTRAZENECA PHARMA IND LT ASTRAZENPharmaceuticals | +20.4% | 8.2% | 107.4x Premium | +75% vs avg | -6.9% |
PROCTER & GAMBLE HEALTH L trades at a discount (30.2x vs peer avg 61.5x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include ALIVUS LIFE SCIENCES LTD, AKUMS DRUGS AND PHARMA L, BLUE JET HEALTHCARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹364 CrJun 2026Latest net profit
₹96 CrJun 2026Latest EPS
₹57.92Jun 2026Net margin
27.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 301 | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 | 374 | 370 | 364 |
| Expenses + | 256 | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 | 263 | 235 | 264 |
| Operating Profit | 45 | 89 | 102 | 67 | 48 | 114 | 123 | 81 | 90 | 120 | 110 | 136 | 100 |
| OPM % | 15% | 29% | 33% | 27% | 17% | 36% | 40% | 26% | 27% | 37% | 30% | 37% | 27% |
| Other Income + | 5 | 6 | 5 | 2 | -18 | 3 | 4 | 3 | 4 | 5 | 4 | 4 | 36 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 6 | 6 |
| Profit before tax | 44 | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 | 109 | 133 | 129 |
| Tax % | 32% | 26% | 28% | 26% | 26% | 26% | 25% | 22% | 25% | 26% | 29% | 29% | 26% |
| Net Profit + | 30 | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 | 78 | 95 | 96 |
| EPS in Rs | 17.96 | 39.50 | 43.42 | 28.05 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 | 57.92 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Press Release / Media Release